Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate and pancreas involvement are linked in IgG4-related disease.

Seminars in arthritis and rheumatism·2020
Same author

The Role of Oxygen Tension in Penile Erection and Its Relationship to Erectile Dysfunction.

TheScientificWorldJournal·2018
Same author

Erectile Dysfunction: AUA Guideline.

The Journal of urology·2018
Same author

Carbon encapsulated nanoscale iron/iron-carbide/graphite particles for EMI shielding and microwave absorption.

Physical chemistry chemical physics : PCCP·2017
Same author

Feasibility of dexmedetomidine as sole analgesic agent during robotic urological surgery: A pilot study.

Journal of anaesthesiology, clinical pharmacology·2017
Same author

PD-1 blockade restores impaired function of ex vivo expanded CD8<sup>+</sup> T cells and enhances apoptosis in mismatch repair deficient EpCAM<sup>+</sup>PD-L1<sup>+</sup> cancer cells.

OncoTargets and therapy·2017
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Central nervous system agents and erectile dysfunction.

Rajeev Kumar1, Ajay Nehra

  • 1Department of Urology, All India Institute of Medical Sciences, New Delhi, India.

The Urologic Clinics of North America
|May 31, 2011
PubMed
Summary
This summary is machine-generated.

Centrally acting agents show promise for erectile dysfunction (ED) treatment, particularly nasal apomorphine and bremelanotide. These options may benefit men unresponsive to or intolerant of PDE5 inhibitors.

Related Experiment Videos

Last Updated: Jun 1, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Pharmacology
  • Urology
  • Men's Health

Background:

  • Erectile dysfunction (ED) affects many men, with limited treatment options for some.
  • Current ED treatments like PDE5 inhibitors have efficacy and tolerability limitations.
  • Centrally acting agents offer a novel therapeutic approach for ED.

Purpose of the Study:

  • To review centrally acting agents for erectile dysfunction.
  • To assess the efficacy and tolerability data of these agents.
  • To identify potential candidates for future ED treatment approval.

Main Methods:

  • Literature review of centrally acting agents for ED.
  • Analysis of available efficacy and tolerability data.
  • Focus on nasal formulations of apomorphine and bremelanotide.

Main Results:

  • Several centrally acting agents demonstrate potential for improving erectile function.
  • Nasal apomorphine and bremelanotide show promise for future approval.
  • These agents may be suitable for specific patient groups, including those failing PDE5 therapy.

Conclusions:

  • Centrally acting agents represent a developing therapeutic class for ED.
  • Nasal formulations of apomorphine and bremelanotide are leading candidates for approval.
  • These treatments could offer valuable alternatives for men with specific ED-related challenges.